With plans under way for pivotal trials with its oral heparinoid for diabetic neuropathy, KRX-101, Keryx Pharmaceuticals Inc. reported positive interim Phase II results - and watched Wall Street take value back from the stock, which had run up starting in late April. (BioWorld Today)